Vaxart does not pay dividends to its shareholders. As a clinical-stage biotechnology company investing heavily into laboratory research, manufacturing scaling, and expensive human clinical trials for its oral pill vaccines, the enterprise retains all available financial capital to fund its ongoing development pipeline. Companies in this early growth and clinical phase prioritize channeling funds back into research and operational expansion rather than distributing cash dividends. Consequently, investors in Vaxart stock seek capital appreciation driven by clinical milestone achievements and commercialization prospects rather than regular income payouts.